Approximately 10-20% of lung adenocarcinoma tumours harbour activating mutations in EGFR. Targeting these mutations clinically with EGFR tyrosine kinase inhibitors such as gefitinib or osimertinib improves survival, however, in the metastatic setting, almost all patients invariably develop drug resistance2. The gene discussed is EGFR; the disease is neoplasm.